In vitro-in vivo extrapolation of clearance: Modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 838-851

  Poulin, Patrick ^a   Kenny, Jane R ^b   Hop, Cornelis E C A ^b   Haddad, Sami ^c  

^a Genentech ^*  (Canada)

^b GENENTECH INC   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Computational ADME; Disposition; Hepatic clearance; In vitro in vivo extrapolation; IVIVE; Metabolic clearance; Microsomes; PBPK modeling; Pharmacokinetics; Unbound fraction

Indexed keywords

ALBUMIN; AMITRIPTYLINE; CHLORPROMAZINE; CLOZAPINE; DIAZEPAM; DICLOFENAC; IBUPROFEN; IMIPRAMINE; LORCAINIDE; METHOXSALEN; MIDAZOLAM; OROSOMUCOID; PROPAFENONE; QUINIDINE; TENIDAP; TENOXICAM; TOLBUTAMIDE; TRIAZOLAM; VERAPAMIL; WARFARIN; ZOLPIDEM;

ARTICLE; CALCULATION; COMPARATIVE STUDY; DRUG BINDING; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; IN VITRO IN VIVO EXTRAPOLATION; IONIZATION; METABOLIC CLEARANCE RATE; MICROSOME; MODEL;

EID: 84455208265     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22792     Document Type: Article

References (58)

1. Faed EM. 1982. Protein binding of drugs in plasma, interstitial fluid and tissues: Effects on pharmacokinetics. Eur J Clin Pharmacol 21:77-81.
2. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
3. Blanchard N, Richert L, Notter B, Delobel F, David P, Coassolo P, Lavé T. 2004. Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur J Pharm Sci 23:189-199.
4. Blanchard N, Alexandre E, Abadie C, Lavé T, Heyb B, Mantion G, Jaeck D, Richert L, Coassolo P. 2005. Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 35:1-15.
5. Blanchard N, Hewitt NJ, Silber P, Jones H, Coassolo P, Lavé T. 2006. Prediction of hepatic clearance using cryopreserved human hepatocytes: A comparison of serum and serum free incubations. J Pharm Pharmacol 58:633-641.
6. Chao P, Uss AS, Cheng KC. 2010. Use of intrinsic clearance for prediction of human hepatic clearance. Expert Opin Drug Metab Toxicol 62:189-198.
7. Chao P, Barminko J, Novik E, Han Y, Maguire T, Cheng KC. 2009. Prediction of human hepatic clearance using in vitro plated hepatocytes clearance model. Drug Metab Lett 3:296-307.
8. Foster JA, Houston BJ, Halifax D. 2011. Comparison of intrinsic clearances in human liver microsomes and suspended hepatocytes from the same donor livers: Clearance-dependent relationship and implications for prediction of in vivo clearance. Xenobiotica 41:124-136.
9. Gariépy L, Fenyves D, Villeneuve JP. 1992. Propranolol disposition in the rat: Variation in hepatic extraction with unbound drug fraction. J Pharm Sci 81:255-258.
10. Ring B, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RDO, Yates JWT, Ku MS, Gibson CR, He H, Vuppugalla R, Marathe P, Fischer V, Dutta S, Sinha VK, Björnsson T, Lavé T, Poulin P. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics. 3. Comparative assessment of prediction methods of human clearance. J Pharm Sci 100:4090-4110.
11. Berezhkovskiy LM. 2010. The corrected traditional equations for calculation of hepatic clearance that account for the difference in drug ionisation in extracellular and intracellular tissue water and the corresponding corrected PBPK equation. J Pharm Sci 100:1167-1183.
12. Berezhkovskiy LM, Khojastech SC, Halladay JS, Hop CE. 2009. On the prediction of hepatic clearance using the diluted plasma in metabolic assay. J Pharm Sci 98:1922-1927.
13. Burczynski FJ, Wang GQ, Elmhadoun B, She YM, Roberts MS, Standing KG. 2001. Hepatocyte palmitate uptake: Effect of albumin surface charge modification. Can J Physiol Pharmacol 79:868-875.
14. Baba T, Touchi A, Ito K, Yamaguchi Y, Yamazoe Y, Ohno Y, Sugiyama Y. 2002. Effect of serum albumin and liver cytosol on CYP2C9 and CYP3A4 drug metabolism. Drug Metab Pharmacokinet 17:522-531.
15. Tang C, Lin Y, Rodrigues DA, Lin JH. 2002. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: An impact more than protein binding. Drug Metab Dispos 30:648-654.
16. Heintz RC, Guentert TW, Enrico JF, Dubach UC, Brandt R, Jeunet FS. 1984. Pharmacokinetics of tenoxicam in healthy volunteers. Eur J Rheumatol Inflamm 7:33-44.
17. Guzman-Hernandez D, Ramirez-Silvia MT, Alarcon-Angeles G, Rojas-Hernandez A. 2008. Effects of β-CD on the electrochemical behavior of tenoxicam. ECS Trans 15:365-370.
18. Smith TM, Eadie MJ, Brophy TO. 1981. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 19:271-278.
19. Reed MD. 2001. Influence of midazolam on the protein binding of ketorolac. Curr Ther Res 62:558-565.
20. Kroboth PD, Smith RB, Sorkin MI, Silver MR, Rault R, Garry M, Juhl RP. 1984. Triazolam protein binding and correlation with alpha-1-acid glycoprotein. Clin Pharmacol Ther 36:379-383.
21. Muret P, Makki S, Urien S, Agache P, Bechtel P, Tillement JP. 1993. Binding of 5-methoxypsoralen to blood fractions. Influence of albumin and free fatty acids: An in vitro study. Skin Pharmacol 6:45-51.
22. Zhou D, Li F. 2004. Protein binding study of clozapine by capillary electrophoresis in the frontal analysis mode. J Pharm Biomed Anal 35:879-885.
23. McGowan FX, Reiter MJ, Pritchett J, Shand DG. 1983. Verapamil plasma binding: Relationship to alpha-1-acid glycoprotein and drug efficacy. Clin Pharmacol Ther 33:485-490.
24. Piafsky KM, Borga O. 1977. Plasma protein binding of basic drugs: Importance of alpha-1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther 22:545-549.
25. Silamut K, Molunto P, Ho M, Davis TM, White NJ. 1991. Alpha-1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br J Clin Pharmacol 32:311-315.
26. Verbeeck RK, Cardinal JA, Wallace SM. 1984. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 27:91-97.
27. Routeledge PA. 1986. The plasma protein binding of basic drugs. Br J Clin Pharmacol 22:499-506.
28. Hong Y, Tang Y, Zeng S. 2009. Enantioselective plasma protein binding of propafenone: Mechanism, drug interaction, and species difference. Chirality 21:692-698.
29. Pacifici GM, Viani A, Rizzo G, Carrai M, Ganansia J, Bianchetti G, Morselli PL. 1988. Plasma protein binding of zolpiderm in liver and renal insufficiency. Int J Clin Pharmacol Ther Toxicol 26:439-443.
30. Divoll M, Greenblatt DJ. 1981. Binding of diazepam and desmethyldiazepam to plasma protein: Concentration-dependence and interactions. Psychopharmacology 75:380-382.
31. Chann KK, Vyas KH, Brandt KD. 1987. In vitro protein binding of diclofenac sodium in plasma and synovial fluid. J Pharm Sci 76:105-108.
32. Proudman KE, McMillan RM. 1991. Are tolfenamic acid and tenidap dual inhibitors of 5-lipoxygenase and cyclo-oxygenase? Agents Actions 34:121-124.
33. Evans L, Aarons L, Coates P. 1999. A pharmacokinetic model for tenidap in normal volunteers and rheumatoid arthritis patients. Pharm Res 16:1608-1615.
34. Kragh-Hansen U, Chuang VT, Otagiri M. 2002. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 25:695-704.
35. Tenoxicam monograph. Accessed July 29, 2011, at:.
36. Peyret T, Poulin P, Krishnan K. 2010. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol Appl Pharmacol 249:197-207.
37. Osterloh K, Ewert U, Pries AR. 2002. Interaction of albumin with the endothelial cell surface. Am J Physiol 283:H398-H405.
38. Qin M, Nilsson M, Øie S. 1994. Decreased elimination of drug in the presence of alpha1-acid-glycoprotein is related to a reduced hepatocytes uptake. J Pharmacol Exp Ther 269:1176-1181.
39. Bilello JA, Biello PA, Stellrecht K, Leonard J, Norbeck DW, Kempf DJ, Robins T, Drusano GL. 1996. Human serum alpha acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Ant Microb Agent Chemother 40:1491-1497.
40. Gordon AH, Humphrey JH. 1961. Measurement of intracellular albumin in rat liver. Biochem J 78:551-556.
41. Judah JD, Nicholls MR. 1971. Biosynthesis of rat serum albumin. Biochem J 123:649-655.
42. Albumin-serum: MedlinePlus Medical Encyclopedia. Nim.nih.gov. Accessed May 12, 2010, at.
43. Poulin P, Ekins S, Theil FP. 2011. A hybrid approach to advancing quantitative prediction of tissue distribution of basic drugs in human. Toxicol Appl Pharmacol 250:194-212.
44. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K. 2009. Prediction of human pharmacokinetics from preclinical information: Comparative accuracy of quantitative prediction approaches. J Clin Pharm 49:513-533.
45. Fagerholm U. 2007. Prediction of human pharmacokinetics: Evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 59:803-828.
46. Pelkonen O, Turpeinen M. 2007. In vitro-in vivo extrapolation of hepatic clearance: Biological tools, scaling factors, model assumptions, and correct concentrations. Xenobiotica 37:1066-1089.
47. Beaumon K, Gardner I, Chapman K, Hall M, Rowland M. 2011. Towards an integrated human clearance prediction strategy that minimizes animal use. J Pharm Sci 100:4518-4535.
48. Kindla J, Muller F, Mieth M, Fromm MF, Konig J. 2011. Influence of non-steroidal anti-inflammatory drugs (NSAIDs) on OATP1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos 257:G584-G593.
49. Burczynski FJ, Cai ZS, Moran JB, Forker EL. 1989. Palmitate uptake by cultured hepatocytes: Albumin binding and stagnant layer phenomena. Am J Physiol 257:G584-G593.
50. Poulin P, Haddad S. 2011. Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. J Pharm Sci 100:4501-4517.
51. Gabellec MM, Steffan AN, Dodeur M, Durang G, Kirn A, Rebel G. 1983. Membrane lipids of hepatocytes, kupffer cells and endothelial cells. Biochem Biophys Res Commun 113:845-853.
52. Rodgers T, Leahy D, Rowland M. 2005. Physiologically based pharmacokinetics modeling 1: Predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94:1259-1267.
53. Boswell AC, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. 2010. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21:2153-2163.
54. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, Hatorri K. 2010. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23:385-392.
55. Mandula H, Parepally JMR, Feng R, Smith QR. 2006. Role of site-specific binding to plasma albumin in drug availability to brain. J Pharmacol Exp Ther 317:667-675.
56. Colombo S, Buclin T, Décosterd LA, Telenti A, Furrer H, Lee BL, Biollaz J, Eap CB. 2006. Orosomucoid (alpha-1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther 80:307-318.
57. Hung DY, Chang P, Cheung K, McWhinney B, Masci PP, Weiss M, Roberts MS. 2002. Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug. J Pharm Exp Ther 301:1079-1087.
58. Haddad S, Poulin P, Funk C. 2010. Extrapolating in vitro metabolic interactions to isolated perfused liver: Prediction of metabolic interactions between bufarolol, bunitrolol and debrisoquine. J Pharm Sci 99:4406-4426.